https://www.live-feeds.com/feed/novartis-pelacarsen-lp-a-trial-fails-raising-doubts-for-amgen-lillyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-pelacarsen-lp-a-trial-fails-raising-doubts-for-amgen-lillyhttps://www.live-feeds.com/feed/novartis-pelacarsen-lp-a-trial-fails-raising-doubts-for-amgen-lilly#u63371Thu, 10 Sep 2026 01:58:27 +0000Novartis announced that a large clinical trial for its heart drug pelacarsen failed to meet expectations. The drug was intended to prevent heart attacks by targeting Lp(a), but the results have shocked cardiologists. This failure creates uncertainty for other companies in the multibillion-dollar race to develop Lp(a) therapies, specifically Amgen and Eli Lilly. The news has contributed to a volatile week for Novartis and triggered a significant stock decline for Amgen.Why it mattersLp(a) is a type of cholesterol that clinicians hoped would be a new target for reducing cardiovascular risk. Pela